Evidence-Based Complementary and Alternative Medicine / 2016 / Article / Tab 3

Review Article

Assessment of the Therapeutic Effect of Total Glucosides of Peony for Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis

Table 3

Subgroup and sensitivity analysis.

TreatmentOutcomesSubgroupNumber of studies and participantsEffect size (SMD, MD, OR, or RR)Effect size, valueHeterogeneity, (%)Heterogeneity, value

Cointervention versus controlOverall response rate7,423
Short term2,141OR = 1.55, 95% CIs, 0.68 to 3.510.29500.963
Intermediate term7,423OR = 2.47, 95 CIs, 1.22 to 5.00.01200.862
Long term2,77OR = 2.11, 95% CIs, 0.56 to 7.930.2700.872
Intermediate term6,339# OR = 2.04, 95% CI 0.93 to 4.470.07400.925
ESR7,379
Short term1,36MD = −4.21 mm/h, 95% CI, −9.31 to 0.89 mm/h0.106
Intermediate term7,379MD = −3.36 mm/h, 95% CI, −5.18 to −1.54 mm/h<0.00158.10.026
Long term2,77MD = −3.72 mm/h, 95% CI, −6.66 to −0.78 mm/h0.01391.70.001
Intermediate term6,328#MD = −2.93 mm/h, 95% CI, −4.92 to −1.44 mm/h<0.00142.30.123
CRP7,379
Short term1,36SMD = −0.53, 95% CI, −1.2 to 0.130.117
Intermediate term7,379SMD = −1.02, 95% CI, −1.67 to −0.360.00288.4<0.001
Long term2,77SMD = −0.61, 95% CI, −1.19 to −0.030.03835.90.211
Intermediate term5,250#SMD = −0.49, 95% CI, −0.82 to −0.150.00541.30.146
Intermediate term6,295#SMD = −0.95, 95% CI, −1.70 to −0.200.01388.7<0.001
DMS4,232
Short term1,36MD = −6.28 min, 95% CI, −16.77 to 4.21 min0.241
Intermediate term4,232MD = −18.46 min, 95% CI, −33.28 to −3.63 min0.01582.70.001
Intermediate term3,148#MD = −10.91 min, 95% CI, −17.69 to −4.12 min0.00200.502
TJC2,87
Short term1,36MD = −2.19, 95% CI: −4.53 to 0.150.066
Intermediate term2,87MD = −2.99, 95% CI: −5.82 to −0.160.03879.90.026
SJC2,87
Short term1,36MD = −2.41, 95% CI: −4.97 to 0.1520.065
Intermediate term2,87MD = −3.05, 95% CI: −6.97 to 0.870.12792.8<0.001
IgGIntermediate term2,87MD = −0.90 g/L, 95% CI: −3.39 to 1.59 g/L0.47880.70.023
IgAIntermediate term2,87MD = −0.48 g/L, 95% CI: −1.05 to 0.10 g/L0.10385.20.009
GSIntermediate term1,84MD = 1.83 kg, 95% CI: 0.68 to 2.98 Kg0.002
Prednisone dosageIntermediate term1,70MD = −2.40 mg/d, 95% CI: −3.75 to −1.05 mg/d0.001
Prednisone treatment durationIntermediate term1,70MD = −56 d, 95% CI: −75.12 to −36.88 d
ACR70Intermediate term1,61OR = 3.61; 95% CI: 1.09 to 11.940.035
JADASIntermediate term1,61MD = −1.75; 95% CI: −2.24 to −1.26

TGP alone versus MTX aloneOverall response rate2,99
Short term1,31OR = 0.60, 95% CI: 0.12 to 3.030.537
Intermediate term2,99OR = 1.26, 95% CI: 0.29 to 5.470.76100.963
DMSIntermediate term1,68MD = −3.36 min, 95% CI: −9.76 to 3.16 min = 0.316
Pain scoreIntermediate term1,68MD = −0.30; 95% CI: −0.53 to −0.07 = 0.010
Doses of prednisoneIntermediate term1,68MD = −2.40 mg/d, 95% CI: −3.96 to −0.84 mg/d = 0.003
Course of prednisoneIntermediate term1,68MD = −56 d, 95% CI: −77.71 to −34.29 d < 0.001
ESRIntermediate term1,68MD = −4.40 mm/h; 95% CI: −10.67 to 1.87 mm/h = 0.169
CRPIntermediate term1,68MD = −1.6 mg/L; 95% CI: −8.53 to 5.34 mg/L = 0.651
AEsOverall5,291OR = 0.38, 95% CI: 0.17 to 0.820.01440.30.153
Cointervention versus control3,192OR = 0.63, 95% CI: 0.30, 1.330.22600.870
TGP alone versus MTX alone2,99OR = 0.14, 95% CI: 0.03, 0.690.01654.90.137

Sensitivity analysis after some studies were dropped out. DMS, duration of morning stiffness; TGP, total glucosides of peony; MTX, Methotrexate; TJC, tender joint count; SJC, swollen joint count; GS, grip strength; AE, adverse effect; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease Activity Score.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.